Latest Breaking News On - Budesonide market - Page 1 : comparemela.com

Share this article Share this article ResearchAndMarkets.com s offering. Sales of Budesonide increased from 2016 to 2019, with a CAGR of approximately 9.26%. However, the sales of Budesonide decreased by 29.30% in 2020 because of the COVID-19 pandemic. The sales revenue in 2020 was approximately CNY1.1 billion. With the improvement of the epidemic situation, the analyst predicts that the sales of Budesonide in China will have a recovery growth in the short run. Budesonide is an adrenal cortex hormone medicine. It is available in different forms, such as inhalant, nasal spray, and so on. The inhalation form is used to treat asthma and chronic obstructive pulmonary disease. The nasal spray form is used to treat allergic rhinitis and nasal polyps.

Chia tai tianqingSynmosa budesonideSynmosa biopharmaLaura woodJishu lunan budesonideOffice hours callChia tai tianqing pharmaceutical group co ltdLunan pharmaceutical group corporationLunan pharmaceutical group corporation jishuAstrazeneca pty ltdE st office hours callSynmosa biopharma corporationDevelopment of budesonideInfluential factors of chinese budesonide market developmentAstrazeneca pty ltd budesonideBudesonide market